New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?

Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in fact increasingly focusing on developing DNA damage repair (DDR) defect-driven no...

Descripción completa

Detalles Bibliográficos
Autores principales: Aurilio, Gaetano, Cimadamore, Alessia, Santoni, Matteo, Nolè, Franco, Scarpelli, Marina, Massari, Francesco, Lopez-Beltran, Antonio, Cheng, Liang, Montironi, Rodolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349416/
https://www.ncbi.nlm.nih.gov/pubmed/32580469
http://dx.doi.org/10.3390/cells9061522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349416/
https://www.ncbi.nlm.nih.gov/pubmed/32580469
http://dx.doi.org/10.3390/cells9061522

Ejemplares similares